Biopharma known for Jakafi/Jakavi (blood-cancer drug) and Opzelura for vitiligo/eczema, with an oncology pipeline.
Biopharma known for Jakafi/Jakavi (blood-cancer drug) and Opzelura for vitiligo/eczema, with an oncology pipeline.
Sells Jakafi itself in the US, while Novartis sells the same drug as Jakavi elsewhere and pays Incyte royalties; royalties also come from Eli Lilly's Olumiant, a related JAK drug. Jakafi has carried the company for years, and Opzelura, a skin cream Incyte sells itself, is its second major product.
Moat: narrow (IP / patents, installed base). First-to-market JAK-inhibitor franchise with an entrenched hematology-oncology prescriber base.
Headquarters: Wilmington, Delaware, United States · Founded: 1991 · Employees: 2,844
Size Incyte (INCY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $24.0B, the 441st largest of 3,085 United States companies the cockpit tracks. Shares closed at $117.80 on 18 Nov 2026.
Performance Over six months the shares gained 21.3%, against +7.6% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 24.9% over the last twelve months (peer median +29.3%); the operating margin is 11.7% (peer median 22.7%).
Valuation It trades at 15.1× forward earnings against a peer median of 22.4× (6th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 21.4 points above its cost of capital (9.0% WACC).
Short interest Short interest is 5.2% of the free float (30 Oct 2026).
Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $6.01B | $5.14B | $4.24B | $3.70B | $3.39B |
| Revenue growth | — | +21% | +15% | +9% | — |
| Gross profit | $5.50B | $4.70B | $3.86B | $3.38B | $3.14B |
| EBITDA | $799M | $1.44B | $169M | $734M | $667M |
| Net income | $403M | $1.29B | $32.6M | $598M | $341M |
| Free cash flow | $685M | $1.35B | $249M | $464M | $892M |
| Capital expenditure | $65.1M | $83.9M | $100M | $47.5M | $77.8M |
| Total debt | $37.4M | $54.9M | $60.3M | $52.6M | $55.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Incyte INCY | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 9.2× | -13.1% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 18.1× | -0.1% |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 17.5× | 1.6% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INCY | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.0% | +6.5% | 6th lowest of 21 |
| 6-month return | +21.3% | +7.6% | 7th highest of 21 |
| Distance from 52-week high | -11.2% | -9.1% | 10th lowest of 21 |
| Revenue growth (TTM) | +24.9% | +29.3% | 10th lowest of 21 |
| Operating margin | 11.7% | 22.7% | 5th lowest of 21 |
| Forward P/E | 15.1× | 22.4× | 6th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 14.2% | 7.7% | 6th most demanding of 19 |
| Growth delivered (Del g) | +14.0% | +12.1% | 8th highest of 19 |
| Hurdle (Req g minus delivered) | +0.2 pp | -13.0 pp | 6th most demanding of 19 |
| ROIC minus cost of capital | +21.4 pp | +7.2 pp | 6th highest of 21 |
| EV / EBITDA | 25.3× | 16.4× | 7th most expensive of 19 |
| Net debt / EBITDA | -4.8× | 0.1× | 3rd least indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Incyte INCY | United States | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% | +14.0% |
| Viatris VTRS | United States | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% | +3.7% |
| Hansoh Pharma 3692.HK | Hong Kong | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% | +10.8% |
| Sigma Healthcare SIG.AX | Australia | $22.4B | +2% | +209% | 9% | 38.4× | 28.9% | +26.1% |
| Insmed INSM | United States | $26.3B | +3% | +240% | -42% | n/a | n/a | n/a |
| Roivant Sciences ROIV | United States | $28.1B | +20% | +102% | -3,234% | n/a | n/a | n/a |
| Alnylam Pharmaceuticals ALNY | United States | $20.0B | -50% | +56% | 20% | 21.2× | 0.5% | +49.8% |
| Innovent Biologics 1801.HK | Hong Kong | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% | +26.8% |
| Torrent Pharmaceuticals TORNTPHARM.NS | India | $18.8B | +3% | +42% | 22% | 70.2× | 37.6% | +11.3% |
| Divi's Laboratories DIVISLAB.NS | India | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% | +8.9% |
| Daiichi Sankyo 4568.T | Japan | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% | +17.1% |
| Astellas Pharma 4503.T | Japan | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% | +11.4% |
| Shionogi & 4507.T | Japan | $17.6B | +3% | +46% | 29% | 11.8× | 0.2% | +11.0% |
| Ascendis Pharma A/S ASND | United States | $16.9B | +12% | +94% | 18% | 28.0× | 19.2% | +152.4% |
| Exelixis EXEL | United States | $16.7B | +37% | +9% | 40% | 17.7× | -3.8% | +18.6% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% | +7.2% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $16.1B | +6% | +15% | 30% | 24.1× | -2.1% | +13.1% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% | +12.5% |
| Orion ORNAV.HE | Finland | $15.7B | +41% | +34% | 38% | 23.6× | -6.2% | +11.7% |
| Biogen BIIB | United States | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% | -5.1% |
| PharmaEssentia 6446.TW | Taiwan | $15.0B | +67% | +78% | 40% | 31.9× | 23.7% | +94.8% |